Equation Of Cockcroft And Gault (Gabapentin Fig1)
Gabapentin Capsule
Product Images NDC 50090-6875
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 50090-6875). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Fig-2 (Gabapentin Fig2)
Fig-3 (Gabapentin Fig3)
Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Gabapentin Fig4)
Figure 3 shows the proportion of responders, in terms of patients with more than 50% reduction in pain score, at the endpoint of controlled PHN studies. The graph shows the percentages of responders for different studies and treatment groups. The x-axis represents the different treatment groups, including PBO, GBP 3600, GBP 1800, and GBP 2400. The y-axis represents the percentage of responders. The graph suggests that the treatments GBP 3600 and GBP 2400 had higher percentages of responders compared to the placebo group (PBO). However, further details about the studies and their results are not available in the given text.*
Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)
Chemical Structure (Gabapentin Str)
Label Image (Lbl500906875)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
